Feds scoop up a band of biotech insiders who allegedly bagged a windfall, and now criminal charges
Early last year, investors in Celator picked up a 72% premium when Jazz swooped in to buy the company and its lead drug for acute myeloid leukemia for $1.5 billion in cash. And according to federal investigators, a CPA at Celator conspired with friends to bag a quick windfall in the buyout and for the positive clinical trial data for Vyxeos that inspired the deal and quadrupled the biotech’s share price.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.